WASHINGTON--(BUSINESS WIRE)--BIO President and CEO Jim Greenwood issued the following statement regarding the news that researchers at the Harvard Stem Cell Institute created 20 disease-specific stem cell lines thru the new induced pluripotent stem cell (iPS) technique:
